Fractyl Health, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Fractyl Health, Inc. now
Current reporting with the operating signal separated from the noise.
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Investors are testing whether Fractyl Health, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Fractyl Health, Inc. Reports Positive Preclinical Data for Rejuva Gene Therapy in Obesity and Diabetes Treatment
The story matters when it changes Fractyl Health, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Fractyl Health, Inc. to Present Preclinical Data on Rejuva Gene Therapy Platform at ASGCT 2025 Annual Meeting
The story matters when it changes Fractyl Health, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript
Investors are testing whether Fractyl Health, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest GUTS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Fractyl Health, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →